|
|
|
NCRRs Division for Biomedical Technology Research and Research Resources (DBTRRR) participates,
along with other NIH components, in two federal grant programs that
provide funding to small businesses. The Small Business Innovation
Research (SBIR) Program and the Small Business Technology Transfer
(STTR) Program both seek to increase the participation of small
businesses in federally supported research and development (R&D)
and to increase private sector commercialization of technology developed
through federally supported R&D. However, there are significant
differences between the two programs. For detailed program information,
refer to the NIH Small
Business Opportunities Web site.
Typically, the DBTRRR requests applications for grants, but it may solicit
contract proposals as well. DBTRRR is especially interested in funding technology-driven research
on new or improved instruments, devices, and related methodologies
that may have broad application to biomedical research.
- (R43-R44) Small Business Innovation Research (SBIR) grants support
domestic small business concerns to engage in research/research
and development that has the potential for commercialization.
Phase I, which uses the R43 funding mechanism, is normally for
six months for an amount up to $100,000. Phase II, which uses
the R44 funding mechanism, is for two years and for up to $750,000.
Receipt deadlines for applications are April 1, August 1, and
December 1 of each year. Refer to the Biomedical
Technology Program Guidelines for appropriate examples of technological
areas of interest to DBTRRR.
- (R41-R42) Small Business Technology Transfer (STTR) grants support
innovative research in the United States that results in commercial
products or services that benefit the public. An STTR grant requires
research partners at universities and other non-profit research
institutions to have a formal collaborative relationship with
the small business concern. At least 40 percent of the STTR research
project is to be conducted by the small business concern and at
least 30 percent of the work is to be conducted by the single,
"partnering" research institution. Phase I, which uses
the R41 funding mechanism, is for one year for an amount up to
$100,000. Normally, Phase II, which uses the R42 mechanism, is
for two years and for up to $500,000. This total includes direct
costs, indirect costs, and fixed fees. If justified, applicants
may propose longer periods of time and greater amounts of funds.
Receipt deadlines for applications are April 1, August 1, and
December 1 of each year. Refer to the Biomedical
Technology Program Guidelines for appropriate examples of technological
areas of interest to DBTRRR.
|
|
| |
For further information, contact:
Director, Division for Biomedical Technology Research and Research Resources
National Center for Research Resources
National Institutes of Health
One Democracy Plaza, Room 962
6701 Democracy Boulevard, MSC 4874
Bethesda, Maryland 20892-4874
Telephone: 301-435-0755
FAX: 301-480-3659
e-mail: BTADIR@mail.nih.gov
|
|